Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL6029 Target Snapshot

Eukaryotic translation initiation factor 2-alpha kinase 1 · SINGLE PROTEIN · Homo sapiens

555Compounds
123Assays
6Approved Drugs
359.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9BQI3. Use UniProt Q9BQI3 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9BQI3 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Eukaryotic translation initiation factor 2-alpha kinase 1 as ChEMBL target CHEMBL6029, mapped to UniProt Q9BQI3. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Eukaryotic translation initiation factor 2-alpha kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL6029
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9BQI3
Eukaryotic translation initiation factor 2-alpha kinase 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Eukaryotic translation initiation factor 2-alpha kinase 1 is the right protein anchor across sources, using UniProt Q9BQI3 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEukaryotic translation initiation factor 2-alpha kinase 1
UniProt AccessionQ9BQI3
Component TypeProtein
Sequence Length630 aa

Eukaryotic translation initiation factor 2-alpha kinase 1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Eukaryotic translation initiation factor 2-alpha kinase 1, mapped to UniProt Q9BQI3. Sequence length is 630 aa.

Mapped IDQ9BQI3
Review nameEukaryotic translation initiation factor 2-alpha kinase 1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

6
Approved
2
Phase III
6
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC5046.0
KD313.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL573760 8.2 IC50 6.31 Preclinical
CHEMBL578426 8.1 IC50 7.943 Preclinical
CHEMBL576168 7.7 IC50 19.95 Preclinical
CHEMBL4281823 7.58 IC50 26.0 Preclinical
CHEMBL574005 7.5 IC50 31.62 Preclinical
CHEMBL2441342 7.43 IC50 37.0 Preclinical
CHEMBL578836 7.3 IC50 50.12 Preclinical
CHEMBL428690 7.24 Kd 58.0 Clinical
CHEMBL2441346 7.21 IC50 61.0 Preclinical
CHEMBL574443 7.2 IC50 63.1 Preclinical
Distribution

pChEMBL Value Distribution

7
5.0
12
5.5
19
6.0
7
6.5
7
7.0
3
7.5
2
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
BARICITINIB
CHEMBL2105759
Approved 2017
DABRAFENIB
CHEMBL2028663
Approved 2013
BOSUTINIB
CHEMBL288441
Approved 2012
Assay Landscape

Assay Landscape

123
Total Assays
60
Tested Compounds
1
Assay Types
Binding — 123 assays, 60 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 81 44 6.4
cell-based format 21 0
assay format 20 0
subcellular format 1 16 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine